Gregory Bierer1, David Balfe, William R Wilcox, Zab Mosenifar. 1. Division of Pulmonary/Critical Care Medicine, Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, California, USA. gregory.bierer@cshs.org
Abstract
BACKGROUND:Fabry disease is an X-linked genetic disorder resulting in the accumulation of glycosphingolipids in various organs, leading to exercise intolerance and early mortality. Enzyme replacement therapy (ERT) has recently been approved for use in Fabry patients. GOALS OF STUDY: To assess baseline cardiopulmonary exercise characteristics in both invasive and noninvasive tests and to study the impact of ERT on exercise. METHODS: A total of 15 patients with Fabry disease underwent baseline cardiopulmonary exercise tests. Six patients were randomized 2:1 to receive either ERT or placebo. We performed serial cardiopulmonary exercise tests at baseline and every 3 months over a period of at least 18 months. The baseline test was compared to the last two exercise tests for each patient. RESULTS:Mean age was 32 years. Mean VO2max was 1.680 +/- 0.67 L/min and increased by 0.459 +/- 0.64 L/min in the patients receiving ERT. Mean VO2max was 1.462 +/- 0.25 L/min and decreased by 0.116 +/- 0.44 L/min in patients on placebo. Mean oxygen pulse (VO2/HR) increased by 1.71 with enzyme, but increased only 0.025 in patients taking placebo. Estimated stroke volume (SV) increased by 10 ml in patients on ERT. CONCLUSIONS: In this small cohort, exercise tolerance increased in patients receiving enzyme replacement therapy. Cardiopulmonary exercise testing is a useful test in measuring the response to therapy in Fabry disease patients.
RCT Entities:
BACKGROUND:Fabry disease is an X-linked genetic disorder resulting in the accumulation of glycosphingolipids in various organs, leading to exercise intolerance and early mortality. Enzyme replacement therapy (ERT) has recently been approved for use in Fabry patients. GOALS OF STUDY: To assess baseline cardiopulmonary exercise characteristics in both invasive and noninvasive tests and to study the impact of ERT on exercise. METHODS: A total of 15 patients with Fabry disease underwent baseline cardiopulmonary exercise tests. Six patients were randomized 2:1 to receive either ERT or placebo. We performed serial cardiopulmonary exercise tests at baseline and every 3 months over a period of at least 18 months. The baseline test was compared to the last two exercise tests for each patient. RESULTS: Mean age was 32 years. Mean VO2max was 1.680 +/- 0.67 L/min and increased by 0.459 +/- 0.64 L/min in the patients receiving ERT. Mean VO2max was 1.462 +/- 0.25 L/min and decreased by 0.116 +/- 0.44 L/min in patients on placebo. Mean oxygen pulse (VO2/HR) increased by 1.71 with enzyme, but increased only 0.025 in patients taking placebo. Estimated stroke volume (SV) increased by 10 ml in patients on ERT. CONCLUSIONS: In this small cohort, exercise tolerance increased in patients receiving enzyme replacement therapy. Cardiopulmonary exercise testing is a useful test in measuring the response to therapy in Fabry diseasepatients.
Authors: C M Eng; N Guffon; W R Wilcox; D P Germain; P Lee; S Waldek; L Caplan; G E Linthorst; R J Desnick Journal: N Engl J Med Date: 2001-07-05 Impact factor: 91.245
Authors: M Beck; R Ricci; U Widmer; F Dehout; A García de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; G Houge; U Ramaswami; A Gal; A Mehta Journal: Eur J Clin Invest Date: 2004-12 Impact factor: 4.686
Authors: L K Brown; A Miller; A Bhuptani; M F Sloane; M I Zimmerman; G Schilero; C M Eng; R J Desnick Journal: Am J Respir Crit Care Med Date: 1997-03 Impact factor: 21.405
Authors: Saskia M Rombach; Bouwien E Smid; Gabor E Linthorst; Marcel G W Dijkgraaf; Carla E M Hollak Journal: J Inherit Metab Dis Date: 2014-02-04 Impact factor: 4.982
Authors: Taciane Alegra; Filippo Vairo; Monica V de Souza; Bárbara C Krug; Ida V D Schwartz Journal: Genet Mol Biol Date: 2012-12-18 Impact factor: 1.771
Authors: Marieke Biegstraaten; Reynir Arngrímsson; Frederic Barbey; Lut Boks; Franco Cecchi; Patrick B Deegan; Ulla Feldt-Rasmussen; Tarekegn Geberhiwot; Dominique P Germain; Chris Hendriksz; Derralynn A Hughes; Ilkka Kantola; Nesrin Karabul; Christine Lavery; Gabor E Linthorst; Atul Mehta; Erica van de Mheen; João P Oliveira; Rossella Parini; Uma Ramaswami; Michael Rudnicki; Andreas Serra; Claudia Sommer; Gere Sunder-Plassmann; Einar Svarstad; Annelies Sweeb; Wim Terryn; Anna Tylki-Szymanska; Camilla Tøndel; Bojan Vujkovac; Frank Weidemann; Frits A Wijburg; Peter Woolfson; Carla E M Hollak Journal: Orphanet J Rare Dis Date: 2015-03-27 Impact factor: 4.123
Authors: Martina Gaggl; Renate Kain; Peter Jaksch; Dominik Haider; Gerald Mundigler; Till Voigtländer; Raute Sunder-Plassmann; Paulus Rommer; Walter Klepetko; Gere Sunder-Plassmann Journal: Case Rep Transplant Date: 2013-04-07
Authors: J W Koskenvuo; J J Hartiala; P Nuutila; R Kalliokoski; J S Viikari; E Engblom; M Penttinen; J Knuuti; I Mononen; I M Kantola Journal: J Inherit Metab Dis Date: 2008-05-23 Impact factor: 4.750